News & Analysis as of

New Legislation › Research and Development › Federal Funding

Seyfarth Shaw LLP

The Week in Weed: May 2025

Seyfarth Shaw LLP on

Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana. This week, the Congressional Cannabis Caucus is hoping to lift the ban on cannabis research. A DC dispensary heard...more

Health Care Compliance Association (HCCA)

‘Waking Up With Panic Attacks’: NIH 15% Plan Caps Tumultuous Weeks Under New Administration

Health Care Compliance Association (HCCA) on

If NIH succeeds in imposing an across-the-board indirect cost rate of 15%, rough estimates indicate the University of Michigan could lose $119 million a year. Emory University could be down $75 million. For the University of...more

Dorsey & Whitney LLP

The CHIPS and Sciences ACT of 2022 - The Impact on China

Dorsey & Whitney LLP on

The CHIPS and Sciences Act of 2022 (the “Act”) was passed by the U.S. Congress on July 27, 2022 and signed into law by President Biden on August 9 of the same year. The Act is an effort to increase semiconductor manufacturing...more

White & Case LLP

President Biden Signs CHIPS and Science Act into Law

White & Case LLP on

On August 9, 2022, President Biden signed the CHIPS and Science Act (H.R.4346), which seeks to bolster the US semiconductor supply chain and promote research and development of advanced technologies in the United States. The...more

Kohrman Jackson & Krantz LLP

Congress Aims To Fund Domestic Technology Businesses

Kohrman Jackson & Krantz LLP on

Last week, just days ahead of the March 11 funding deadline, President Biden signed into law a $1.5 trillion Omnibus budget, the Consolidated Appropriations Act of 2022, to fund federal agencies for the rest of the year....more

Ballard Spahr LLP

Obama Signs 21st Century Cures Act, Adding $6.3 Billion For Medical Research

Ballard Spahr LLP on

The Cures Act aims to increase the speed by which new drugs are brought to market by streamlining clinical trials, allowing the use of patient data in the regulatory review process, and modernizing U.S. Food and Drug...more

6 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide